What the assistants say
This snapshot covers 1,250 answers from ChatGPT, Claude, Gemini, Perplexity and Grok, collected on 2026-09-29 from 250 benchmark questions that named no company. The answers frequently declined to pick a winner. On trust, insurer coverage and prior authorization, the sampled answers said the result depends on the plan, the state or the survey used, and then listed names anyway.
Brands split by question type. On customer-service questions, CVS Health was the most-named brand, followed by UnitedHealth Group and Cigna. On coverage and access to care, UnitedHealth Group led, followed by Cigna and CVS Health. On leadership and scale, Johnson & Johnson, Merck and Eli Lilly came first. Sustainability and ethics questions pointed most often to AstraZeneca. Innovation questions pointed to Eli Lilly.
Risk questions ran the other way. On "avoid and risk" questions, Johnson & Johnson and Pfizer were the most-named brands. In the sampled answers, litigation, settlements, withdrawn drugs and data breaches were the hooks. One example was the Change Healthcare breach, which Gemini and Perplexity attached to UnitedHealth Group.
There isn’t a single universal “most trusted” pharma company…
Who owns the answer, and why
Johnson & Johnson was named most often, in 192 of 1,250 answers. UnitedHealth Group (179), CVS Health (174), Pfizer (174), Merck (158) and Eli Lilly (155) followed. Grok named every tracked brand more often than the other assistants did. For Johnson & Johnson the figure was 60 of 250 Grok answers, against 29 for ChatGPT.
The credit tags are thin. For Johnson & Johnson, Pfizer, CVS Health and Merck, the largest classified category was "Not Substantive": the brand was named in a list without being credited for a specific quality. Where credit was specific, it was Customer Experience for CVS Health, Safety & Compliance for Johnson & Johnson and Pfizer, Price & Value for Eli Lilly, and Financial Performance and Sustainability & Ethics for AstraZeneca.
Some names that appear in the answer text are not among the tracked brands. Humana, Aetna, Walgreens, Novartis, GSK and Roche come up repeatedly in sampled answers. Among the tracked brands, Moderna (31 answers), Gilead Sciences (50) and Elevance Health (64) sit at the bottom.
It is difficult to pinpoint a single "most complained about" insurer because there is no national, centralized database that tracks all consumer complaints…
What the press is covering
PeakMetrics' 30-day news index shows heavy coverage for the drugmakers. Merck had 20,731 mentions, Amgen 20,317, Eli Lilly 19,681, Pfizer 19,027 and Johnson & Johnson 15,472. Pfizer had the most headlines with the brand in the title (3,546). Much of the recent headline flow is investor-style material: stock moves, holdings filings and valuation pieces on Johnson & Johnson, Merck, Cigna, Elevance Health and Gilead Sciences.
Story-driven headlines stand out in the sample. UnitedHealth Group appeared alongside a John Oliver segment on the Luigi Mangione sentencing, an Optum Florida deal and margin pressures. Eli Lilly appeared with an FDA approval, a $2.9 billion acquisition and a missing-executive story. Novo Nordisk appeared with a NYSE listing comment, pressure to outline growth beyond Wegovy and a rebrand. Several Pfizer, Moderna and Johnson & Johnson headlines came from brighteon.com, covering COVID vaccines and baby powder. Several Amgen headlines were about the Amgen Irish Open golf tournament, not the company.
There isn’t one national insurer that consistently covers fertility treatment best…
Where the two stories diverge
Coverage volume does not predict answer presence. Amgen had 20,317 news mentions in the index but was named in 69 answers. Merck had 20,731 mentions and 158 answers. Moderna had 9,921 mentions and 31 answers. The payers run the other way: UnitedHealth Group had 6,360 mentions, CVS Health 6,043 and Cigna 6,048, yet each was named in 125 to 179 answers, largely because the question set asks about coverage, pharmacies and service.
The content differs too. The press narrative for these brands leans toward markets, deals and trial results. The assistant narrative leans toward service, coverage, price, litigation and breaches. A brand can dominate one and barely register in the other.
What this means for comms teams
Check which question type you are attached to, not just whether you are named. The same company can own "customer service" in one set of answers and "avoid and risk" in another. Because many answers said "it depends", the evidence they cite matters more than a single verdict.
The cited domains are mostly trade and reference sources. Trade sites make up 51% of the source mix, News 12% and Review & Affiliate 7%. The most-cited domains were pmc.ncbi.nlm.nih.gov, beckershospitalreview.com, fda.gov, forbes.com, fiercepharma.com, cms.gov, goodrx.com and healthline.com. Wire and press-release volume is not obviously what is being cited. The citation data covers corporate and reputational prompts, not consumer product queries.
This is a single snapshot of live answers, and answers vary between runs. Use it to see which storylines are attached to you today, then compare with your own coverage.
